Osstem Implant’s international expansion began in the mid-2000s. Starting with Taiwan in 2005, the company established its first wave of overseas subsidiaries across 12 countries—Germany, India, Russia, China, Hong Kong, Singapore, Japan, the US, Thailand and Malaysia in 2006, followed by Australia in 2007. These subsidiaries developed product portfolios tailored to local market conditions and clinical environments, and localised clinical education and sales expertise.

These early overseas operations laid the groundwork for Osstem Implant’s current global footprint, which includes an export network reaching more than 100 countries. This year, Osstem Implant marks 20 years since the start of its international expansion and plans to further accelerate overseas market development.

Osstem Implant attributes its international growth to three core strengths: product quality supported by sustained R&D investment, a business model enabling close engagement with dental professionals, and a comprehensive clinical education system. Since its founding, the company has invested approximately 11% of annual revenue in R&D. Its central research institute comprises about 30,000 m² of research facilities, including around 10,000 m² of laboratory space, and employs more than 900 researchers.

The flagship Osstem Master Course follows a step-by-step curriculum aligned with dentists’ levels of clinical experience. More than 150,000 dentists worldwide have completed its education programmes to date. A direct-sales structure in overseas markets has supported close communication between local subsidiaries and clinicians, and the company says it will continue to strengthen locally driven strategies across R&D, education and sales.